Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a tiny dose of radiation slow Parkinson's? mayo clinic launches first test.

NCT ID NCT07218952

Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study at Mayo Clinic tests whether ultra-low, anti-inflammatory doses of radiation can slow Parkinson's disease. Twenty people with early-stage Parkinson's will receive five daily radiation treatments guided by special brain scans. The main goal is to see if the treatment reduces motor symptom progression over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
radiation therapy (ultra-low dose, anti-inflammatory)
What this could lead to
If it works, this could point toward a new way to slow Parkinson's progression using targeted, low-dose radiation.
What could go wrong
This is a very early, small study (20 people) with no control group. The radiation approach is experimental and may not slow the disease or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Age ≥ 45 and ≤ 70 years * Diagnosis of Parkinson's disease by a Movement Disorder Neurologist * Confirmation of unilateral Parkinson's disease by Dopamine Transporter (DaT) scan * A score of 2 or less on the modified Hoehn and Yahr scale * ECOG Performance Status (PS) ≤ 2 (Appendix I). * No known genetic causes or predisposition to Parkinson's disease or related diseases. * Ability to complete questionnaires, neurological exam, and follow-up imaging independently or with assistance * Ability to provide written informed consent * Willing to provide mandatory blood samples for correlative research purposes * Willing to return to enrolling institution for follow-up Exclusion Criteria * Concomitant dementia diagnosis or concerns of other memory disorder * Parkinson's Disease medication changes within the last 3 months * Receipt of radiation therapy for Parkinson's Disease outside Mayo Clinic, Rochester

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson's disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neurodegenerative disease Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson's disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.